Interní Med. 2006; 8(5): 219-222

Diabetes mellitus and hypertension

MUDr. Erik Hollay1, MUDr. Pavlína Pi»hová2, doc. MUDr. Milan Kvapil CSc2
1 Diabetologické centrum, Interní klinika 2. LF UK a FN Motol, Praha
2 Interní klinika fakultní nemocnice Motol a 2. lékařské fakulty Univerzity Karlovy v Praze

Arterial hypertension is a disease with high prevalence in developed countries and continues to be a current problem. From the diabetelogy point of view it is considered to be one of the components of metabolic syndrome and belongs to the most important risk factors of cardiovascular mortality. Authors attempted to summarize the treatment modalities of arterial hypertension in diabetic patients in connection with results of clinical trials.

Keywords: Key words: diabetes mellitus type 1 and 2, hypertension, nonpharmacological therapy, antihypertensive medications, ACE inhibitors, angiotensin II receptor blockers, beta blockers, calcium channel blockers.

Published: June 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hollay E, Pi»hová P, Kvapil M. Diabetes mellitus and hypertension. Interní Med. 2006;8(5):219-222.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R, et al. za Českou společnost pro hypertenzi: Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Vnitřní lék., 50, 2004; 9: 709-722.
    2. Haffner SM, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without previous myocardial infarction implications treatment of hyperlipidemia in diabetic subjects without prior myocardial infarction. N Engl J Med. 339; 1998; 229-234. Go to original source... Go to PubMed...
    3. Hansson L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular mortality and morbidity in hypertension: the Captopril Prevention Project (CAPP). Lancet, 353; 1999; 611-616. Go to original source... Go to PubMed...
    4. Lindholm LH, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hyperten., 20; 2002; 1879-1886. Go to original source... Go to PubMed...
    5. The Antihypertensive and Lipid - Lovering treatment to prevent Heart Attack Trial (ALLHAT). JAMA, 288; 2002; 1981-1997.
    6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or inzulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352; 1998; 837-853. Go to original source...
    7. UK Prospective Diabetes Study (UKPDS) Group. Efficiacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. BMJ. 317; 1998; 713-720. Go to original source...
    8. Working Party of the International Diabetes Federation. Hypertension in people with Type 2 Diabetes: knowledge-based diabetes-specific guidelines. Diabetic Medicine, 2003; 20: 972-987. Go to original source... Go to PubMed...
    9. Deedwania PC. Hypertension and diabetes: New therapeutic options. Arch Intern Med 2000; 160: 1585-1594. Go to original source... Go to PubMed...
    10. Charvát J, et al. Diabetes mellitus a makrovaskulární komplikace. 1. vydání, Praha: Triton, 2001: 203 s.
    11. The Seventh Report of the JNC on prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA, 2003; 289: 2560-2572.
    12. Ruggenetenti P, et al. Preventing Microalbuminuria in Type 2 Diabetes. N. Engl. J. Med., 2004; 351: 1941-1951. Go to original source... Go to PubMed...
    13. Widimský J, a kolektiv: Hypertenze. 2. vydání, Praha: Triton, 2004.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.